Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of...

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Pharmacology

Background:

• The link between high-density lipoprotein cholesterol (HDL-C) and cardiovascular risk is established, but recent drug trials failed to show benefits.
• This has cast doubt on the
• HDL hypothesis,
• prompting a re-evaluation of HDL's role and therapeutic targeting.

Purpose of the Study:

• To review reasons for the failure of HDL-C-raising drugs in clinical trials.
• To highlight the importance of novel biomarkers and translational models in understanding HDL metabolism.
• To propose a unified mechanism for HDL's antioxidant and cholesterol transport functions.

Main Methods:

• Review of recent large-scale phase III studies on HDL-C-raising agents.
• Analysis of the interaction between apolipoprotein A1 (ApoA1) and ATP-binding cassette transporter A1 (ABCA1).
• Investigation of HDL's role in intestinal sterol and antioxidant uptake.

Main Results:

• Pharmaceutical compounds designed to raise HDL-C have not translated to clinical benefits.
• The interaction between ApoA1 and ABCA1 may be key to both cholesterol efflux and intestinal uptake of sterols/antioxidants.
• Current assessment of HDL-raising drugs may be insufficient, overlooking intestinal absorption mechanisms.

Conclusions:

• The failure of HDL-C-raising drugs may stem from a limited understanding of HDL metabolism and inadequate translational models.
• A unified mechanism involving ApoA1-ABCA1 interaction explains both reverse cholesterol transport and antioxidant functions.
• Future drug development should consider both intestinal uptake and cholesterol efflux for assessing HDL-raising agents.